Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy

Vaccine

Volumn 25, Issue 29, 2007, Pages 5324-5329

  Lao araya, Mongkol ^a   Puthanakit, Thanyawee ^b   Aurpibul, Linda ^b   Sirisanthana, Thira ^b   Sirisanthana, Virat ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Hepatitis B vaccine; Human immunodeficiency virus (HIV)

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE; VIRUS RNA;

ANTIBODY RESPONSE; ARTICLE; CHILD; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVACCINATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; MALE; RNA, VIRAL; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 34250886260     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.006     Document Type: Article

References (30)

1. Homann C., Krogsgaard K., Pedersen C., Andersson P., and Nielsen J.O. High incidence of hepatitis B infection and evaluation of chronic hepatitis B infection in patients with advance HIV infection. J Acquir Immune Defic Syndr 4 4 (1991) 416-420
2. Gilson R.J., Hawkins A.E., Beecham M.R., Ross E., Waite J., Briggs M., et al. Interaction between HIV and hepatitis B virus in homosexual men: effect on natural history of infection. AIDS 11 5 (1997) 597-606
3. Horvath J., and Raffanti S.P. Clinical aspects of the interaction between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 18 3 (1994) 339-347
4. Thio C.L., Seaberg E.C., Skolasky Jr. R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B, and risk of liver-related mortality in multicenter AIDS Cohort Study (MACS). Lancet 360 9349 (2002) 1921-1926
5. Moss W.J., Clements C.L., and Halsey N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 81 1 (2003) 61-70
6. Fonseca M.O., Pang L.W., Cavalheiro N.P., Barone A.A., and Lopes M.H. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 23 22 (2005) 2902-2908
7. Rey D., Krantz V., Partisani M., Schmitt M., Meyer P., Libbrecht E., et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patient. Effect on HIV-1 viral load. Vaccine 18 13 (2000) 1161-1165
8. Thaithumyanon P., Puhnahitanonda S., Prisuwanna P., Thisyakorn P., and Ruxrungtham K. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai 85 3 (2002) 277-282
9. Zuin G., Principi N., Tornagi R., Paccagnini S., Re M., Massironi E., et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 10 12 (1992) 857-860
10. Scolfaro C., Fiammengo P., Balbo L., Madon E., and Tovo P.A. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 10 10 (1996) 1169-1170
11. Rutstein R.M., Ruby B., and Codispoti C. Response to hepatitis B immunization by infants exposed to HIV. AIDS 8 9 (1994) 1281-1284
12. Arrazola M.P., de Juanes J.R., Ramos J.T., Aragon A.J., and Garcia de Codes A. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol 45 3 (1995) 339-341
13. Siriaksorn S., Puthanakit T., Sirisanthana T., and Sirisanthana V. Prevalence of protective antibody levels against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 24 16 (2006) 3095-3099
14. Zanetti A.R., Mariano A., Romano L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 9494 (2005) 1379-1384
15. Obaro S.K., Pugatch D., and Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1 infected children. Lancet Infect Dis 4 8 (2004) 510-518
16. Puthanakit T., Oberdorfer A., Akarathum N., Kanjanavanit S., Wannarit P., Sirisanthana T., et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis 41 1 (2005) 100-107
17. Melvin A.J., and Mohan K.M. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 111 6 (2003) 641-644
18. Centers of Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the US through universal childhood vaccination. Recommendation of the Immunization Practices Advisory Committee (ACIP). Morb Mortal Wkly Rep 40 RR-13 (1991) 1-25
19. Centers of Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morb Mortal Wkly Rep 43 (1994) 1-10
20. Poovorawan Y., Theamboonlers A., Vimolket T., Sinlaparatsamee S., Chaiear K., Siraprapasiri T., et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine 19 7-8 (2000) 943-949
21. Cassidy W.M., Watson B., Ioli V.A., Williams K., Bird S., and West D.J. A randomised trial of alternative two- or three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107 4 (2001) 626-631
22. Tayal S.C., and Sankar K.N. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV infected individuals. AIDS 8 4 (1994) 558-559
23. Wong E.K.L., Bodsworth N.J., Slade M.A., Mulhall B.P., and Donovan B. Response to hepatitis B vaccination in primary care setting: influence of HIV infection CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 7 (1996) 490-494
24. Desombere I., Gijbels Y., Verwulgen A., and Leroux-Roels G. Characterization of T cell recognition in hepatitis B surface antigen by good and poor responders to hepatitis B vaccines. Clin Exp Immunol 122 3 (2000) 390-399
25. Veiga A.P., Casseb J., and Duarte A.J. Humeral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 24 49-50 (2006) 7124-7128
26. Overton E.T., Sungkanuparph S., Powderly W.G., Seyfried W., Groger R.K., and Aberg J.A. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 41 7 (2005) 1045-1048
27. Weinberg A., Gona P., Nechman S.A., Defechereux P., Yoger R., Hughes W., et al. Antibody response to hepatitis A vaccine among HIV-infected children with evidence of immunologic reconstitution on antiretroviral therapy. J Infect Dis 193 2 (2006) 302-311
28. Levin M.J., Gershon A.A., Weinberg A., Song L.Y., Fentin T., Nowak B., et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis 194 2 (2006) 247-255
29. Andersson J., Fehniger T.E., Patterson B.K., Pottage J., Agnoli M., Jones P., et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 12 (1998) F123-F129
30. Pontesilli O., Kerkhof-Garde S.R., Notermans D.W., Foudraine N.A., Roos M.T., Klein M.R., et al. Functional T cell reconstruction and HIV-1 specific cell-mediated immunity during highly active antiretroviral therapy (HAART). J Infect Dis 180 1 (1999) 76-86